BTG, a specialist healthcare company, has reported that its VANISH-1 and VANISH-2 studies have 'demonstrated efficacy in achieving a clinically meaningful improvement' in the appearance of the legs of patients with varicose veins.
The studies found that 80% of patients treated with either the 0.5% or 1.0% dose concentrations reported a much or moderate improvement of symptoms.
Patients treated in this study were representative of a typical varicose veins population, with an age range of 21 to 73. Side effects were mostly mild or moderate.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Dr Kenneth Todd, a Principal Investigator for VANISH-2 said: "Current treatments for patients with medically-important, symptomatic varicose veins are time-consuming for both patients and physicians and do not offer a comprehensive treatment.
"The publication of the full results for VANISH-1 and VANISH-2 confirm the top-line results already reported and demonstrate that the product, if approved, could offer an effective, comprehensive treatment option for patients with symptomatic varicose veins."
NR
